To provide a crystalline form of a compound as a mineralcorticoid receptor antagonist and a preparation method thereof as well as an application in the preparation of a medicament in which the crystalline form of a compound treats and/or prevents nephropathy or cardiovascular disease.SOLUTION : The present invention belongs to the field of pharmaceutical technology, and relates to a crystalline form of a compound as a mineralocorticoid receptor antagonist and a preparation method thereof, specifically, a preparation method of a compound represented by the formula (1) 2-chloro-4-[(3S, 3aR)-3-cyclopentyl-7-(4-hydroxypiperidine-1-carbonyl)-3, 3a, 4, 5-tetrahydro-2H-pyrazolo[3, 4-f]quinolin-2-yl]benzonitrile, a crystalline form thereof, a method for preparing the crystalline form as well as an application in the preparation of a medicament in which the crystalline form treats and/or prevents nephropathy or cardiovascular disease.SELECTED DRAWING : None